GORE RECEIVES FDA APPROVAL OF GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS FOR THE REPAIR OF LESIONS OF THE DESCENDING THORACIC AORTA

Approval brings first flexible, off-the-shelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment.

May 13, 2022

GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS

CAUTION: Investigational device. Limited by United States law to investigational use.

Apr 12, 2022

GORE® CARDIOFORM SEPTAL OCCLUDER MARKS 10 YEARS OF IMPROVING LIVES

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care.

Jan 19, 2022

Gore Receives FDA Approval for the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System

The innovative device and delivery system combine proven conformability with new levels of control.

Jan 6, 2021

W. L. GORE & ASSOCIATES ANNOUNCES ENCOURAGING SIX-MONTH RESULTS WITH ITS NOVEL BIOSYNTHETIC TISSUE VALVE

At the American Heart Association Virtual Scientific Sessions 2020.

Nov 18, 2020

W. L. Gore & Associates enhances GORE® VIABAHN® Endoprosthesis portfolio with lower profile delivery

Improvements to large diameter devices include accessiblity through smaller sheaths while providing enhanced visualization under fluoroscopy

Sep 22, 2020

W. L. Gore & Associates Marks 20 Years of Improving and Extending Life for Patients with Liver Cirrhosis Complications

As liver disease prevalence grows worldwide, earlier TIPS intervention with the GORE® VIATORR® TIPS Endoprosthesis has proven to increase survival and to reduce complications of liver cirrhosis over conventional therapies.1

Aug 25, 2020